FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound of formula (I), as well as a pharmaceutical composition based thereon for inhibiting WEE1 and methods of attenuating or treating cancer or attenuating or treating a malignancy or tumour by inhibiting WEE1.
EFFECT: obtaining new compounds that have the ability to inhibit WEE1 and can be used to treat a disease mediated by this activity.
32 cl, 42 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | 2007 |
|
RU2437885C2 |
| BENZAMIDE COMPOUNDS | 2019 |
|
RU2801647C2 |
| BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
| QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | 2010 |
|
RU2528412C2 |
| MONOACYLGLYCEROL LIPASE MODULATORS | 2019 |
|
RU2797323C2 |
| PYRIMIDINE COMPOUND WITH CONDENSED RINGS, ITS INTERMEDIATE COMPOUND, METHOD OF PRODUCING, COMPOSITION AND USE | 2016 |
|
RU2732576C2 |
| CD73 INHIBITOR, ITS PRODUCTION METHOD AND ITS USE | 2020 |
|
RU2787428C1 |
| PHOSPHOINOSITIDE-3-KINASE INHIBITORS AND METHODS FOR USE THEREOF | 2007 |
|
RU2468027C2 |
| PYRAZOLE DERIVATIVES APPLIED AS PROTEIN KINASE INHIBITORS | 2001 |
|
RU2340611C2 |
| AVB6 INTEGRIN INHIBITORS | 2018 |
|
RU2769702C2 |
